Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anavex Lf SC (NQ: AVXL )

3.455 +0.065 (+1.92%)
Streaming Delayed Price Updated: 3:16 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Lf SC

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Anavex Life Sciences Q1 Earnings
  Anavex Life Sciences (NASDAQ:AVXL) reported its Q1 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - February 04, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life... 
Via NewMediaWire
Investigation Notice: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. 
Via Benzinga
ANAVEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Anavex Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
23 Stocks Moving in Wednesday's Pre-Market Session
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix... 
Via Benzinga
Mid-Afternoon Market Update: Dow Rises 50 Points; DLH Holdings Shares Drop
US stocks traded mixed in the afternoon session on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact
Just two weeks ago, Anavex edited the goals of its study in Rett syndrome. 
Via Investor's Business Daily
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K... 
Via Benzinga
Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb
US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views
US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including... 
Via Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key... 
Via Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares in... 
Via Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Earnings Scheduled For November 24, 2021
Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life... 
Via Benzinga
Earnings Outlook For Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.